Widening the door: The evolution of hepatitis C treatment in patients with psychiatric disorders

Hepatology

Volumn 46, Issue 4, 2007, Pages 957-959

  Geppert, Cynthia M A ^b   Arora, Sanjeev ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; INTERFERON;

ADDICTION; ALCOHOL ABUSE; BIPOLAR DISORDER; COMORBIDITY; DEPRESSION; EDITORIAL; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOMETRY; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; SUBSTANCE ABUSE; TREATMENT RESPONSE;

ANTIVIRAL AGENTS; DEPRESSION; HEPATITIS C; HUMANS; MENTAL DISORDERS; RISK FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 36348960812     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21891     Document Type: Editorial

References (18)

1. Rosenberg SD, Swanson JW, Wolford GL, Osher FC, Swartz MS, Essock SM, et al. The five-site health and risk study of blood-borne infections among persons with severe mental illness. Psychiatr Serv 2003;54:827-835.
2. Dieperink E, Willenbring M, Ho SB. Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: a review. Am J Psychiatry 2000;157:867-876.
3. Hosoda S, Takimura H, Shibayama M, Kanamura H, Ikeda K, Kumada H. Psychiatric symptoms related to interferon therapy for chronic hepatitis C: clinical features and prognosis. Psychiatry Clin Neurosci 2000;54:565-572.
4. Falck-Ytter Y, Kale H, Mullen KD, Sarbah SA, Sorescu L, McCullough AJ. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-292.
5. Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects. HEPATOLOGY 2007;46. DOI: 10.1002/hep.21791.
6. Management of hepatitis C. NIH Consens Statement 1997;15:1-41.
7. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C: June 10-12, 2002. HIV Clin Trials 2003;4:55.
8. Knott A, Dieperink E, Willenbring ML, Heit S, Durfee JM, Wingert M, et al. Integrated psychiatric/medical care in a chronic hepatitis C clinic: effect on antiviral treatment evaluation and outcomes. Am J Gastroenterol 2006; 101:2254-2262.
9. Geppert CM, Arora S. Ethical issues in the treatment of hepatitis C. Clin Gastroenterol Hepatol 2005;3:937-944.
10. Geppert CM, Dettmer E, Jakiche A. Ethical challenges in the care of persons with hepatitis C infection: a pilot study to enhance informed consent with veterans. Psychosomatics 2005;46:392-401.
11. Dobmeier M, Frick E, Frank S, Franke C, Wolfersdorf M. Schizophrenic psychosis: a contraindication for treatment of hepatitis C with interferon alpha? Pharmacopsychiatry 2000;33:72.
12. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. J Affect Disord 2002;72:237-241.
13. Pariante CM, Orru MG, Baita A, Farci MG, Carpiniello B. Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders. Lancet 1999;354:131-132.
14. Dieperink E, Ho SB, Thuras P, Willenbring ML. A prospective study of neuropsychiatric symptoms associated with interferon-alpha-2b and ribavirin therapy for patients with chronic hepatitis C. Psychosomatics 2003; 44:104-112.
15. Maddock C, Baita A, Orru MG, Sitzia R, Costa A, Muntoni E, et al. Psychopharmacological treatment of depression, anxiety, irritability and insomnia in patients receiving interferon-alpha: a prospective case series and a discussion of biological mechanisms. J Psychopharmacol 2004;18: 41-46.
16. Sylvestre DL. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend 2002;67:117-123.
17. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC: Government Printing Office; 1979.
18. Davis GL. New therapies: oral inhibitors and immune modulators. Clin Liver Dis 2006;10:867-880.